Session: Innovation Showcase: Close to the Patient - Addressing formulation challenges in development of novel therapies
Innovation Showcase Close to the Patient - Addressing formulation challenges in development of novel therapies
Tuesday, July 9, 2024
6:00 PM – 7:30 PM CET
Location: Sala Europa
Sponsored By
DSM Biomedical has developed the TheraPEA™ polyester amide platform of polymers. When loaded with an API, these degradable polymers enable sustained drug release. They enable controlled degradation kinetics without acidification of the microenvironment – making them highly compatible with pH sensitive APIs. TheraPEA™ polymers can be customized to exhibit a multi-month, controlled-release, zero-order degradation profile from weeks to more than 6 months. They also show good correlation in-vitro and in-vivo across a wide range of indications.
